Sarep­ta lands a valu­able pri­or­i­ty re­view vouch­er on Ex­ondys 51 OK

The FDA has is­sued a pri­or­i­ty re­view vouch­er to Sarep­ta, which it’s al­ready been hawk­ing to deep-pock­et drug de­vel­op­ers.

The biotech won the PRV — good to any­one who buys it for a speedy agency re­view four months short­er than the norm — af­ter win­ning ap­proval for eteplirsen. The drug is now be­ing sold for $300,000 a year as Ex­ondys 51, the first drug ap­proved for Duchenne mus­cu­lar dy­s­tro­phy in the US.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.